InflaRx (IFRX) Operating Income Growth (3y) (2021 - 2026)
InflaRx (IFRX) Operating Income Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 69.02% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 24.14% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 44.54% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 44.34% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -28.30% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 81.27% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -18.82% |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,953.53% |
| Dec 31, 2025 | 93.51% |
| Sep 30, 2025 | -8.54% |
| Jun 30, 2025 | -132.76% |
| Mar 31, 2025 | 6.39% |
| Dec 31, 2024 | 72.22% |
| Sep 30, 2024 | -3.96% |
| Jun 30, 2024 | 0.51% |
| Mar 31, 2024 | -12.38% |
| Dec 31, 2023 | -35.10% |
| Sep 30, 2023 | 98.83% |
| Jun 30, 2023 | -0.55% |
| Mar 31, 2023 | 98.98% |
| Dec 31, 2022 | -25.99% |
| Sep 30, 2022 | 99.21% |
| Jun 30, 2022 | 60.08% |
| Mar 31, 2022 | -10.29% |
| Dec 31, 2021 | -36.11% |
| Sep 30, 2021 | -15.24% |
| Jun 30, 2021 | -20.08% |